Studies have found that patients with both anti-CASPR2 and anti-LGI1 antibodies are at risk of thymoma.[17,18] In some tumor-associated syndromes, neurological deficits may occur before the tumor is detected, so patients with negative malignancy should be followed for a long time. This evidence concerns the gene CNTNAP2 and thymoma.